Tseng Sheng-Hong, Chen Yun, Chang Chun-Jung, Tai Kuo-Feng, Lin Swei-Ming, Hwang Lih-Hwa
Department of Surgery, National Taiwan University Hospital, College of Medicine, 7 Chung-Shan South Road, Taipei 100, Taiwan.
Clin Cancer Res. 2005 Feb 15;11(4):1639-49. doi: 10.1158/1078-0432.CCR-04-1366.
To evaluate antitumor effects on intracerebral gliomas of genetically engineered tumor vaccines expressing granulocyte-macrophage colony-timulating factor (GM-CSF), B7.1, or both (combination).
A rat glioma cell line, RT-2, was engineered with a retroviral vector to express GM-CSF, B7.1, or combination. Tumorigenicity of engineered cells and therapeutic effects of s.c. given irradiated or live tumor vaccines on parental intracerebral gliomas were studied. Immune cell infiltration induced at vaccine and tumor sites was examined by histologic and immunohistochemical staining. Apoptosis of T cells from vaccine sites was analyzed with fluorescence-activated cell sorting.
Engineered RT-2 cells exhibited reduced s.c. tumorigenicity in rats with reduced tumor growth and prolonged animal survival time compared with control rats. Rats with intracerebral gliomas s.c. treated with irradiated or live GM-CSF-expressing vaccines had 60% and 100% survival rates, respectively, significantly better than the control groups (P < 0.05). In contrast, rats treated with vaccines expressing B7.1 or the combination had no or mild therapeutic effects. Studies revealed less T-cell infiltration at both vaccine and tumor sites in rats treated with vaccines expressing B7.1 or the combination than in rats treated with a vaccine expressing GM-CSF. Cell sorting analyses revealed higher proportions of apoptotic T cells at vaccine sites of rats treated with the combination than those treated with vaccine expressing GM-CSF.
Combination of GM-CSF- and B7.1-expressing tumor vaccines exerted no synergistic, or even worse, therapeutic effects on gliomas compared with single GM-CSF-secreting tumor vaccine. The worse therapeutic effects of the GM-B7.1-expressing tumor vaccine than the GM-CSF-expressing tumor vaccine were related to the reduced T-cell amount and increased T-cell apoptosis in the former.
评估表达粒细胞-巨噬细胞集落刺激因子(GM-CSF)、B7.1 或二者兼具(联合)的基因工程肿瘤疫苗对脑内胶质瘤的抗肿瘤作用。
用逆转录病毒载体改造大鼠胶质瘤细胞系 RT-2,使其表达 GM-CSF、B7.1 或二者联合。研究改造后细胞的致瘤性以及皮下注射经照射的或活的肿瘤疫苗对亲本脑内胶质瘤的治疗效果。通过组织学和免疫组织化学染色检查疫苗和肿瘤部位诱导的免疫细胞浸润情况。用荧光激活细胞分选法分析来自疫苗部位的 T 细胞凋亡情况。
与对照大鼠相比,改造后的 RT-2 细胞在大鼠体内皮下致瘤性降低,肿瘤生长减缓,动物存活时间延长。皮下接种经照射的或活的表达 GM-CSF 的疫苗治疗的脑内胶质瘤大鼠,生存率分别为 60%和 100%,显著优于对照组(P<0.05)。相比之下,接种表达 B7.1 或联合疫苗的大鼠无治疗效果或仅有轻微治疗效果。研究显示,接种表达 B7.1 或联合疫苗的大鼠,其疫苗和肿瘤部位的 T 细胞浸润少于接种表达 GM-CSF 疫苗的大鼠。细胞分选分析显示,接种联合疫苗的大鼠疫苗部位凋亡 T 细胞的比例高于接种表达 GM-CSF 疫苗的大鼠。
与单一分泌 GM-CSF 的肿瘤疫苗相比,表达 GM-CSF 和 B7.1 的联合肿瘤疫苗对胶质瘤没有协同治疗效果,甚至治疗效果更差。表达 GM-B7.1 的肿瘤疫苗治疗效果比表达 GM-CSF 的肿瘤疫苗更差,这与前者 T 细胞数量减少和 T 细胞凋亡增加有关。